Christina Annunziata, MD, PhD of National Institutes of Health explains how the phase 2-3 design decreases the number of patients required to deliver results of clinical trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Phase 2-3 Design Decreases The Number of Patients Required To Deliver Results
